A Phase 1 / 2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors
Latest Information Update: 20 Dec 2021
At a glance
- Drugs Paclitaxel (Primary)
- Indications Cancer; Carcinoma; Dermatofibrosarcoma; Ewing's sarcoma; Malignant melanoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abraxis BioScience; Celgene Corporation
- 15 Jun 2020 Primary endpoint has not been met. (Phase 2: Overall Response Rate (ORR))
- 15 Jun 2020 Results of phase II portion of this study (n=42) published in the European Journal of Cancer.
- 05 Dec 2018 Status changed from active, no longer recruiting to completed.